flow trial semaglutide kidney outcomes nejm 2024 hazard ratio 0.76 🔴Cardiovascular with by severity of chronic disease in type 2 diabetes: the trial⤵️ 🔹Semaglutide significantly reduced the risk of CV death/MI/stroke regardless of baseline CKD severity in participants FLOW clinical Trial (funded by
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 8 - Nov 13





















![Blaze [Portal Second Age] GG43](https://cdn.shopify.com/s/files/1/0824/7345/1830/products/7e2e1cc1-9bf9-569a-bbec-db3ca74c5a20_b578d549-6da5-4552-8d37-353f237fde88.jpg?v=1697584712)

![Counterspell [Friday Night Magic 2005] 080](https://cdn.shopify.com/s/files/1/0824/7345/1830/products/ff881018-2aa6-5a28-b12a-51154f90e872_f247aa22-51db-43af-9eeb-f45d4a9d5932.jpg?v=1697584712)

